Vontobel Holding Ltd. Invests $2.43 Million in Acelyrin, Inc. (NASDAQ:SLRN)

Vontobel Holding Ltd. purchased a new position in Acelyrin, Inc. (NASDAQ:SLRN) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 325,549 shares of the company’s stock, valued at approximately $2,429,000.

Other hedge funds have also recently made changes to their positions in the company. China Universal Asset Management Co. Ltd. purchased a new stake in Acelyrin in the 4th quarter valued at about $84,000. SG Americas Securities LLC acquired a new stake in shares of Acelyrin in the 4th quarter worth $110,000. Vanguard Group Inc. grew its stake in Acelyrin by 3.8% during the 3rd quarter. Vanguard Group Inc. now owns 3,189,027 shares of the company’s stock worth $32,432,000 after buying an additional 116,847 shares during the last quarter. Citigroup Inc. purchased a new stake in shares of Acelyrin during the third quarter worth about $745,000. Finally, Deutsche Bank AG purchased a new stake in Acelyrin during the 3rd quarter worth approximately $156,000. 87.31% of the stock is currently owned by institutional investors.

Acelyrin Trading Down 2.8 %

NASDAQ SLRN opened at $4.88 on Friday. The stock has a 50-day simple moving average of $7.26 and a two-hundred day simple moving average of $7.83. Acelyrin, Inc. has a fifty-two week low of $4.76 and a fifty-two week high of $29.88.

Acelyrin (NASDAQ:SLRN) last posted its earnings results on Thursday, March 28th. The company reported ($0.75) EPS for the quarter, topping the consensus estimate of ($1.00) by $0.25. On average, research analysts anticipate that Acelyrin, Inc. will post -4.18 earnings per share for the current year.

Insider Transactions at Acelyrin

In related news, CEO Shao-Lee Lin sold 15,701 shares of the business’s stock in a transaction on Tuesday, February 20th. The shares were sold at an average price of $7.60, for a total value of $119,327.60. Following the completion of the transaction, the chief executive officer now directly owns 1,587,335 shares in the company, valued at approximately $12,063,746. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Analyst Ratings Changes

Several equities analysts recently issued reports on the company. Wells Fargo & Company upped their target price on Acelyrin from $11.00 to $13.00 and gave the company an “equal weight” rating in a research report on Thursday, March 21st. HC Wainwright reaffirmed a “buy” rating and set a $28.00 target price on shares of Acelyrin in a report on Monday, April 1st. Three analysts have rated the stock with a hold rating and four have given a buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $23.67.

About Acelyrin

Acelyrin, Inc, a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis.